Homepage

Indaptus Therapeutics, Inc.

INDP NASDAQ Categories PDF
Healthcare · Biotechnology · United States · Updated May 11, 5:22am
$1.88
Price
$3.3M
Market Cap
7
Employees
1.39
Beta
Junyi Dai
CEO
Business Description

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Business History
Price Overview
Last updated: May 11, 2026 1:52pm (just now)
$1.74
-0.14 (-7.44%)
Day Range
$1.74 – $1.87
52-Week Range
$1.51 – $19.91
50-Day MA
$2.20
200-Day MA
$3.28
Volume
30,098.34
Share Structure
Outstanding 1,751,018.00
Float 1,425,433.00
Free Float 81.4%
High free float — 81.4% of shares trade freely, ~18.6% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (1.4M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-0.09
Stock Price: $1.88
EPS (Diluted): -21.58
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
0.89
Stock Price: $1.88
Total Equity: $3.15M
Shares: 966,124
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
0.26
Market Cap: $3.29M
Total Debt: $0.00
Cash: $8.51M
EBITDA: -$19.83M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
-$5.7M
Market Cap: $3.29M
Total Debt: $0.00
Cash: $8.51M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
0.0%
Operating Income: -$19.83M
Revenue: $0.00
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
0.0%
Net Income: -$20.85M
Revenue: $0.00
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
-938.7%
Net Income: -$20.85M
Total Equity: $3.15M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-629.3%
Operating Income: -$19.83M
Tax Rate: 0.0%
Equity: $3.15M
Total Debt: $0.00
Cash: $8.51M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.51
Current Assets: $9.31M
Current Liabilities: $6.16M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $3.15M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 966,124
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$3.26
Total Equity: $3.15M
Shares: 966,124
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-15.34
Operating CF: -$14.82M
CapEx: -$4.00
Shares: 966,124
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.88
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$20.85M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares INDP against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0
Cost of Revenue $0 $0 $0 $0 $0
Gross Profit $0 $0 $0 $0 $0
Operating Expenses $7.7M $14.9M $16.4M $15.4M $19.8M
Operating Income -$7.7M -$14.9M -$16.4M -$15.4M -$19.8M
Net Income -$7.7M -$14.3M -$15.4M -$15.0M -$20.8M
EBITDA -$7.7M -$14.9M -$16.4M -$15.4M -$19.8M
EPS $-1.89 $-1.73 $-1.84 $-1.61 $-21.58
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $39.1M $9.6M $13.4M $5.8M $8.5M
Total Current Assets $40.4M $27.2M $14.0M $6.6M $9.3M
Total Assets $40.6M $28.1M $14.9M $7.3M $9.3M
Current Liabilities $4.6M $3.4M $2.8M $3.4M $6.2M
Long-Term Debt $0 $0 $0 $0 $0
Total Liabilities $4.7M $3.4M $2.8M $3.4M $6.2M
Total Equity $35.9M $24.6M $12.1M $3.9M $3.2M
Retained Earnings -$15.7M -$30.0M -$45.4M -$60.4M -$81.3M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$11.3M -$13.1M -$13.4M -$12.3M -$14.8M
Capital Expenditure $-3,854 $-172,555 $0 $0 $-4
Free Cash Flow -$11.3M -$13.3M -$13.4M -$12.3M -$14.8M
Acquisitions (net) $451,600 $172,555 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash $37.5M -$29.5M $3.7M -$7.6M $2.7M
Analyst Estimates (Annual)
Metric 2026 2027 2028 2029
Revenue $0 $0 $42.4M
$42.4M – $42.4M
 $123.0M
$123.0M – $123.0M
EBITDA $0 $0 $0 $0
Net Income -$6.1M
-$6.1M – -$6.1M
 -$4.3M
-$4.3M – -$4.3M
 $763,238
$763,238 – $763,238
 $6.2M
$6.2M – $6.2M
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth — — — —
Gross Profit Growth — — — —
Operating Income Growth -92.9% -9.8% +6.2% -29.1%
Net Income Growth -85.7% -7.7% +2.6% -38.8%
EBITDA Growth -92.9% -9.8% +6.2% -29.1%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-04-08 Lu Qinglai 0.00 $0.00 $0
2026-03-23 Yao Yun 0.00 $0.00 $0
2026-03-23 SINO LION VENTURES Ltd 0.00 $0.00 $0
2026-03-23 Dai Junyi 0.00 $0.00 $0
2026-03-23 Lazar David E. S-Sale 196,800.00 $0.00 $0
2026-03-23 Lazar David E. S-Sale 700,000.00 $0.00 $0
2026-02-26 Jabbour Jerome D A-Award 25,000.00 $2.06 $51,500
2026-02-26 Jabbour Jerome D 0.00 $0.00 $0
2026-02-26 McMurdo Matthew Charles 0.00 $0.00 $0
2026-02-11 Meckler Jeffrey A A-Award 12,136.00 $1.75 $21,238
2026-02-11 Meckler Jeffrey A A-Award 3,033.00 $1.75 $5,308
2026-02-11 Meckler Jeffrey A A-Award 1,519.00 $1.75 $2,658
2026-02-11 Meckler Jeffrey A D-Return 12,136.00 $8.30 $100,729
2026-02-11 Meckler Jeffrey A D-Return 3,033.00 $47.60 $144,371
2026-02-11 Meckler Jeffrey A D-Return 1,519.00 $29.40 $44,659
2026-01-20 Ben-Tzvi Avraham A-Award 25,000.00 $0.00 $0
2025-12-23 Ben-Tzvi Avraham A-Award 25,000.00 $1.95 $48,750
2026-01-07 NATAN DAVID A-Award 25,000.00 $2.69 $67,250
2026-01-08 NATAN DAVID 0.00 $0.00 $0
2025-12-22 Sassi Nir A-Award 26,758.00 $2.03 $54,319
Community AI Feedback
Sign in to Contribute
No community reviews yet for INDP. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27